Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

WOK vs SENS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SENS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

SENS Overall Winner 6-Pillar Tally: WOK 3 – 3 SENS Matrix Metrics: WOK 3 – 7 SENS

As of Nov 16, 2026, Senseonics Holdings, Inc. (SENS) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). WOK carries a Unified Composite Score of 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin), whereas SENS carries 38.9/100 (SELL) at $10.90 (21.0x Forward P/E, -201.0% operating margin).

  • Defensive Composite Rating Caution: Although SENS compares more favorably head-to-head, both WOK (25.6/100 SELL) and SENS (38.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WOK vs SENS
WOK NASDAQ
WORK Medical Technology Group LTD Class A Ordinary Shares
Surgical & Medical Instruments & Apparatus
$1.23
+2.5% 1D
Market Cap $5.4M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 38.49β · 153% Vol
Unified Composite Score
25.6 / 100 SELL
Tech 5.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $1.13 · SMA50: $1.47
SENS NYSE American Head-to-Head Winner
Senseonics Holdings, Inc.
Industrial Instruments For Measurement, Display, And Control
$10.90
+3.02% 1D
Market Cap $579.6M
TTM Revenue $60M
Forward P/E 21.0x
Beta / 30D Vol 1.98β · 101% Vol
Unified Composite Score
38.9 / 100 SELL
Tech 15.0 Fund 44.0 Flow 57.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.5% over 20 days), RSI 64
RSI-14: 64.1 · SMA20: $9.04 · SMA50: $9.20

6-Pillar Scorecard Institutional Category Breakdown (WOK 3 – 3 SENS)

Columns: Metric · WOK · SENS
1. Valuation Multiples SENS
Forward P/E N/M 21.0x
Trailing P/E N/M 21.0x
PEG Ratio N/M N/M
EV / Revenue 0.5x 9.9x
2. Growth & Scale SENS
Revenue Growth (YoY) +19.1% +141.6%
Earnings Growth (YoY) -95.0% +0.0%
TTM Revenue (USD) $11M $60M
Market Cap $5.4M $579.6M
3. Profitability & Quality WOK
Gross Margin 17.0% 58.7%
Operating Margin -41.7% -201.0%
Net Profit Margin -41.9% -204.2%
Return on Equity (ROE) -19.2% -157.3%
4. Balance Sheet & Cash Flow WOK
Cash Generation (TTM) -$3.4M EBITDA -$114M
Cash Flow Margin -31.4% EBITDA Mgn N/A
Net Cash / Leverage $1855.16 Book/Sh · -19.2% ROE $13M Net Debt (0.79x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SENS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 68.8% (35th %ile)
Put/Call OI Skew N/A 0.14x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat WOK
OpEx & R&D Intensity 58.7% of Rev ($6.3M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WOK (3) vs SENS (7)
Institutional Metric WOK SENS Criterion Row Edge
Market Capitalization
Scale
$5.4M $579.6M Larger Scale SENS
Trailing P/E Ratio
Valuation
N/M 21.0x Lower Multiple SENS
Forward P/E Ratio
Valuation
N/M 21.0x Lower Multiple SENS
Revenue Growth (YoY)
Growth
+19.1% +141.6% Higher Growth SENS
Operating Margin (TTM)
Profitability
-41.7% -201.0% Higher Margin WOK
Net Profit Margin
Profitability
-41.9% -204.2% Higher Margin WOK
Return on Equity (ROE)
Capital Efficiency
-19.2% -157.3% Higher ROE WOK
52-Week Range Position
Momentum
16% ($0–$7) 66% ($5–$14) Stronger Trend SENS
Beta / 30D Volatility
Risk Regime
38.49β · 153% Vol 1.98β · 101% Vol Lower Realized Risk SENS
Unified Institutional Score
Composite Signal
25.6 / 100 (SELL) 38.9 / 100 (SELL) Higher Composite SENS
Trailing 12M Revenue (USD)
Operating Scale
$11M $60M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
17.0% 58.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.5x EV/Rev N/M PEG · 9.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.4M EBITDA ($1855.16 Book/Sh · -19.2% ROE) -$114M ($13M Net Debt (0.79x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SENS +27.44 pp
WOK: +12.84% · SENS: +40.28%
3M Horizon SENS +69.52 pp
WOK: -44.09% · SENS: +25.43%
6M Horizon WOK +127.64 pp
WOK: +223.68% · SENS: +96.04%
1Y Horizon SENS +148.43 pp
WOK: -72.05% · SENS: +76.38%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on WOK vs SENS. Trailing 12-month operating profitability (WOK -41.7% vs SENS -201.0%) and valuation multiples (WOK N/M vs SENS 21.0x Forward P/E) are benchmarked directly in Pillar 4 below.

WOK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin17.0%
Op. Margin-41.7%
ROE / Fwd P/E-19.2% · N/M
SENS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$60M
Gross Margin58.7%
Op. Margin-201.0%
ROE / Fwd P/E-157.3% · 21.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WOK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SENS CONSOLIDATION
37d in phase · OBV ACCUMULATION
Current IV 68.8%
IV Percentile 35th %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SENS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WOK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.4M market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment 58.7% of Rev ($6.3M)
90D Engineering Disclosures 0 Published
SENS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $579.6M market capitalization and -201.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ WOK vs SENS Key Questions & Quantitative Answers

As of Nov 16, 2026, Senseonics Holdings, Inc. (SENS) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). WOK carries a Unified Composite Score of 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin), whereas SENS carries 38.9/100 (SELL) at $10.90 (21.0x Forward P/E, -201.0% operating margin). Defensive Composite Rating Caution: Although SENS compares more favorably head-to-head, both WOK (25.6/100 SELL) and SENS (38.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SENS leads the Growth & Scale pillar: WOK posts +19.1% YoY revenue growth and -95.0% YoY earnings growth on $11M TTM revenue (17.0% gross margin, -41.7% operating margin), compared with SENS at +141.6% YoY revenue growth and +0.0% YoY earnings growth on $60M TTM revenue (58.7% gross margin, -201.0% operating margin). On trailing 12-month operating scale, WOK generates $11M in USD-normalized revenue versus $60M for SENS. In operating R&D and SG&A reinvestment, WOK deploys 58.7% of Rev ($6.3M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SENS.

SENS screens cheaper on headline valuation multiples. WOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-31.4% EBITDA margin), whereas SENS trades at 21.0x Forward P/E, 21.0x Trailing P/E, N/M PEG, and 9.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WOK (-19.2% ROE) versus SENS (-157.3% ROE) capital efficiency.

In options market volatility and institutional positioning, WOK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (38.49β · 153% Vol realized risk). By comparison, SENS carries 68.8% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.98β · 101% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.